Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

Dr David Stamler Biotech Showcase Presentation

January 8, 2018August 16, 2022 Kerry Rowe

Prana Biotechnology JPM investor presentation_updated

2018

Post navigation

Prana meeting with investors at world’s largest healthcare conference in San Francisco

PBT434 poster presented at the 6th International Multiple System Atrophy Conference

Related Posts

Link to XBRL Interactive Data 30 June 2018

September 3, 2018August 16, 2022

Appendix 4C – Q4 FY22 Quarterly Cash Flow Report

July 22, 2022August 16, 2022

European Union Regulatory Guidance for ATH434 Phase 2 Clinical Trial

June 23, 2021August 16, 2022

Recent Posts

Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy
XBRL 30 June 2022 filed with the SEC
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe
Appendix 4C – Q4 FY22 Quarterly Cash Flow Report
Alterity Therapeutics Doses First Patient in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

Recent Comments

Archives

Archives

Categories

ASX Announcements
Investor Announcement

Tags

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065